 Christopher Porter
Concepts (336)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Germ-Line Mutation | 7 | 2022 | 140 | 2.230 |
Why?
| | Proto-Oncogene Proteins c-ets | 5 | 2022 | 53 | 2.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2023 | 278 | 1.970 |
Why?
| | Leukemia | 5 | 2023 | 229 | 1.900 |
Why?
| | Leukemia, Myeloid, Acute | 9 | 2023 | 592 | 1.600 |
Why?
| | Pyrimidines | 6 | 2017 | 459 | 1.580 |
Why?
| | Interleukin-12 | 3 | 2022 | 118 | 1.530 |
Why?
| | Neoplastic Syndromes, Hereditary | 3 | 2024 | 38 | 1.370 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 75 | 1.360 |
Why?
| | Repressor Proteins | 5 | 2022 | 406 | 1.270 |
Why?
| | Pyrazoles | 4 | 2017 | 404 | 1.270 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 26 | 1.260 |
Why?
| | Thrombocytopenia | 4 | 2020 | 186 | 1.220 |
Why?
| | Genetic Testing | 3 | 2021 | 428 | 1.130 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 584 | 1.120 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2017 | 432 | 1.080 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 56 | 1.000 |
Why?
| | Nuclear Proteins | 3 | 2017 | 659 | 0.980 |
Why?
| | Hematopoietic Stem Cells | 6 | 2021 | 381 | 0.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 1556 | 0.820 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 140 | 0.740 |
Why?
| | Genetic Predisposition to Disease | 9 | 2021 | 2276 | 0.730 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 2 | 2013 | 25 | 0.720 |
Why?
| | RNA, Small Interfering | 6 | 2018 | 591 | 0.680 |
Why?
| | Neoplasms | 6 | 2023 | 2449 | 0.670 |
Why?
| | Cytarabine | 3 | 2017 | 57 | 0.640 |
Why?
| | Gene Knockdown Techniques | 4 | 2019 | 316 | 0.630 |
Why?
| | Calcineurin | 1 | 2019 | 98 | 0.600 |
Why?
| | Pyrimidinones | 5 | 2017 | 103 | 0.600 |
Why?
| | Cell Line, Tumor | 13 | 2022 | 3202 | 0.600 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2013 | 91 | 0.590 |
Why?
| | Hematologic Diseases | 2 | 2015 | 61 | 0.590 |
Why?
| | Apoptosis | 9 | 2022 | 2499 | 0.580 |
Why?
| | CDC2 Protein Kinase | 1 | 2017 | 31 | 0.570 |
Why?
| | Neoplasm Proteins | 3 | 2021 | 422 | 0.560 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2017 | 39 | 0.560 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 13 | 0.550 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 13 | 0.550 |
Why?
| | Mice | 20 | 2023 | 16915 | 0.550 |
Why?
| | Tumor Microenvironment | 5 | 2023 | 631 | 0.540 |
Why?
| | Thioguanine | 3 | 2013 | 18 | 0.540 |
Why?
| | Phthalazines | 1 | 2017 | 41 | 0.540 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2054 | 0.540 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 129 | 0.490 |
Why?
| | Piperazines | 2 | 2017 | 341 | 0.480 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2017 | 509 | 0.480 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.460 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 68 | 0.440 |
Why?
| | Cytokines | 4 | 2023 | 2013 | 0.440 |
Why?
| | DNA Repair | 1 | 2015 | 206 | 0.440 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 118 | 0.420 |
Why?
| | Humans | 52 | 2024 | 129271 | 0.410 |
Why?
| | Transduction, Genetic | 1 | 2013 | 128 | 0.400 |
Why?
| | Bone Marrow | 3 | 2022 | 271 | 0.400 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2018 | 812 | 0.400 |
Why?
| | Drug Synergism | 4 | 2015 | 370 | 0.390 |
Why?
| | Animals | 20 | 2023 | 35309 | 0.390 |
Why?
| | Drug Resistance | 2 | 2013 | 166 | 0.380 |
Why?
| | DNA-Binding Proteins | 3 | 2024 | 1446 | 0.370 |
Why?
| | Leukemia, Experimental | 1 | 2011 | 27 | 0.360 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 54 | 0.360 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2017 | 756 | 0.360 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 26 | 0.350 |
Why?
| | Child | 18 | 2024 | 20785 | 0.350 |
Why?
| | Genomics | 3 | 2022 | 717 | 0.330 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2009 | 21 | 0.310 |
Why?
| | Vincristine | 1 | 2009 | 108 | 0.300 |
Why?
| | Influenza Vaccines | 2 | 2004 | 532 | 0.300 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2009 | 125 | 0.290 |
Why?
| | Triazoles | 1 | 2009 | 151 | 0.280 |
Why?
| | Flow Cytometry | 4 | 2019 | 1155 | 0.280 |
Why?
| | Purines | 1 | 2008 | 172 | 0.270 |
Why?
| | Cell Separation | 1 | 2008 | 316 | 0.270 |
Why?
| | DNA Damage | 3 | 2017 | 383 | 0.250 |
Why?
| | Medical Oncology | 3 | 2023 | 270 | 0.250 |
Why?
| | Organ Transplantation | 1 | 2008 | 228 | 0.240 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 857 | 0.240 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1173 | 0.240 |
Why?
| | Female | 21 | 2024 | 68556 | 0.230 |
Why?
| | Influenza B virus | 1 | 2004 | 37 | 0.220 |
Why?
| | Syndrome | 2 | 2023 | 339 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2019 | 572 | 0.220 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 9 | 0.210 |
Why?
| | Mutation | 5 | 2024 | 3710 | 0.210 |
Why?
| | Interferon-gamma | 2 | 2017 | 772 | 0.210 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.200 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2022 | 1 | 0.200 |
Why?
| | Thrombopoiesis | 1 | 2022 | 8 | 0.200 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2016 | 197 | 0.190 |
Why?
| | Adaptive Immunity | 1 | 2023 | 161 | 0.190 |
Why?
| | Germ Cells | 1 | 2022 | 59 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 22 | 0.190 |
Why?
| | Urogenital Abnormalities | 1 | 2022 | 52 | 0.190 |
Why?
| | Thrombopoietin | 1 | 2021 | 5 | 0.190 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5439 | 0.190 |
Why?
| | Immunization | 1 | 2004 | 411 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2022 | 104 | 0.180 |
Why?
| | Genes, p53 | 2 | 2012 | 70 | 0.180 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 15 | 0.180 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 19 | 0.170 |
Why?
| | Mobile Applications | 1 | 2023 | 160 | 0.170 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 33 | 0.170 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 76 | 0.170 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 49 | 0.160 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 33 | 0.160 |
Why?
| | Leukemia, Myeloid | 1 | 2019 | 45 | 0.160 |
Why?
| | Phenotype | 4 | 2023 | 3074 | 0.160 |
Why?
| | Cell Line | 5 | 2021 | 2779 | 0.160 |
Why?
| | Tumor Escape | 1 | 2019 | 39 | 0.160 |
Why?
| | Up-Regulation | 3 | 2018 | 839 | 0.150 |
Why?
| | NADPH Oxidases | 2 | 2017 | 108 | 0.150 |
Why?
| | Dendritic Cells | 1 | 2022 | 479 | 0.150 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 6 | 0.150 |
Why?
| | Osmoregulation | 1 | 2018 | 3 | 0.150 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2022 | 381 | 0.150 |
Why?
| | PAX5 Transcription Factor | 1 | 2018 | 14 | 0.150 |
Why?
| | Histone Deacetylases | 1 | 2020 | 212 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2023 | 1117 | 0.150 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
| | Anemia, Macrocytic | 1 | 2018 | 4 | 0.150 |
Why?
| | Disease Management | 2 | 2019 | 588 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2022 | 340 | 0.150 |
Why?
| | Interferon-alpha | 1 | 2019 | 194 | 0.150 |
Why?
| | Disease Progression | 2 | 2019 | 2630 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 890 | 0.140 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 9 | 0.140 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 29 | 0.130 |
Why?
| | Hepatoblastoma | 1 | 2017 | 41 | 0.130 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 44 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2021 | 959 | 0.130 |
Why?
| | Infant | 5 | 2021 | 8975 | 0.130 |
Why?
| | Family | 1 | 2021 | 644 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2017 | 77 | 0.130 |
Why?
| | RNA | 1 | 2022 | 880 | 0.120 |
Why?
| | Calcitriol | 1 | 2016 | 55 | 0.120 |
Why?
| | Genotype | 1 | 2021 | 1835 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1933 | 0.120 |
Why?
| | Prednisolone | 1 | 2015 | 82 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1109 | 0.120 |
Why?
| | Pediatrics | 1 | 2003 | 1049 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2011 | 4077 | 0.120 |
Why?
| | Male | 14 | 2024 | 63517 | 0.120 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 169 | 0.120 |
Why?
| | Hemorrhage | 1 | 2019 | 678 | 0.120 |
Why?
| | Telemedicine | 1 | 2023 | 789 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 938 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2017 | 756 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2003 | 1267 | 0.110 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.110 |
Why?
| | Child, Preschool | 6 | 2024 | 10459 | 0.110 |
Why?
| | S Phase | 2 | 2012 | 75 | 0.110 |
Why?
| | Pyridones | 1 | 2015 | 159 | 0.110 |
Why?
| | Thiazoles | 1 | 2014 | 117 | 0.110 |
Why?
| | Blotting, Western | 2 | 2017 | 1204 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2015 | 313 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 95 | 0.100 |
Why?
| | Down Syndrome | 1 | 2019 | 477 | 0.100 |
Why?
| | Cyclosporine | 1 | 2014 | 263 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2017 | 369 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2013 | 88 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1056 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 476 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2017 | 2375 | 0.100 |
Why?
| | Umbilical Cord | 1 | 2013 | 83 | 0.100 |
Why?
| | Vitamin D | 1 | 2016 | 385 | 0.100 |
Why?
| | Tankyrases | 1 | 2012 | 14 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 194 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 131 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1207 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 141 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2018 | 1887 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 74 | 0.090 |
Why?
| | Immunity, Innate | 1 | 2017 | 803 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 266 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2012 | 127 | 0.090 |
Why?
| | Inflammation | 1 | 2022 | 2737 | 0.090 |
Why?
| | Adult | 9 | 2024 | 35497 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 53 | 0.090 |
Why?
| | Lymphocytes | 1 | 2013 | 378 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 328 | 0.090 |
Why?
| | Kidney | 1 | 2018 | 1385 | 0.090 |
Why?
| | Aging | 1 | 2021 | 1774 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 942 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 314 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 947 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2023 | 230 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 392 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2021 | 5736 | 0.080 |
Why?
| | Cell Cycle | 2 | 2012 | 589 | 0.080 |
Why?
| | Cyclophilin A | 1 | 2009 | 26 | 0.080 |
Why?
| | Basigin | 1 | 2009 | 25 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2011 | 200 | 0.080 |
Why?
| | Voriconazole | 1 | 2009 | 20 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2012 | 605 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 8 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 2879 | 0.080 |
Why?
| | Lentivirus | 1 | 2008 | 53 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 6391 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1004 | 0.070 |
Why?
| | Protein Folding | 1 | 2009 | 264 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2008 | 312 | 0.070 |
Why?
| | Adolescent | 5 | 2024 | 20315 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 94 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2019 | 361 | 0.060 |
Why?
| | Hodgkin Disease | 1 | 2007 | 133 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1688 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 5409 | 0.060 |
Why?
| | MutL Protein Homolog 1 | 1 | 2024 | 12 | 0.060 |
Why?
| | MutS Homolog 2 Protein | 1 | 2024 | 14 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2703 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2018 | 696 | 0.060 |
Why?
| | B-Lymphocytes | 2 | 2020 | 815 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2716 | 0.060 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2004 | 38 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2024 | 47 | 0.050 |
Why?
| | DNA Replication | 1 | 2005 | 227 | 0.050 |
Why?
| | Serologic Tests | 1 | 2004 | 52 | 0.050 |
Why?
| | Survival Rate | 1 | 2008 | 1869 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1247 | 0.050 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2005 | 327 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2004 | 178 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 271 | 0.050 |
Why?
| | Receptors, Thrombopoietin | 1 | 2021 | 5 | 0.050 |
Why?
| | Rare Diseases | 1 | 2022 | 99 | 0.050 |
Why?
| | Middle Aged | 3 | 2019 | 31091 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2021 | 35 | 0.050 |
Why?
| | Mice, Nude | 2 | 2014 | 682 | 0.050 |
Why?
| | Disease Susceptibility | 1 | 2023 | 333 | 0.050 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 248 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 428 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 308 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2023 | 275 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 32 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4057 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 978 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1005 | 0.040 |
Why?
| | CD3 Complex | 1 | 2020 | 103 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 12392 | 0.040 |
Why?
| | Prognosis | 1 | 2008 | 3773 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2014 | 10202 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2020 | 114 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2004 | 601 | 0.040 |
Why?
| | Penetrance | 1 | 2019 | 27 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 742 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2342 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 621 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2007 | 831 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 428 | 0.040 |
Why?
| | Hypertonic Solutions | 1 | 2018 | 7 | 0.040 |
Why?
| | Polymers | 1 | 2023 | 477 | 0.040 |
Why?
| | DNA | 1 | 2005 | 1396 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 587 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 160 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2018 | 223 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 635 | 0.040 |
Why?
| | Muramidase | 1 | 2017 | 77 | 0.030 |
Why?
| | Incidence | 1 | 2024 | 2636 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2017 | 137 | 0.030 |
Why?
| | Peroxidase | 1 | 2017 | 174 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 301 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 752 | 0.030 |
Why?
| | Europe | 1 | 2017 | 363 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3377 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 592 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 362 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2015 | 28 | 0.030 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2015 | 29 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2015 | 38 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 112 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2117 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 193 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 2015 | 11 | 0.030 |
Why?
| | Vaccination | 1 | 2004 | 1347 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2024 | 1143 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 6 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 11 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 16 | 0.030 |
Why?
| | Chloroquine | 1 | 2014 | 51 | 0.030 |
Why?
| | Exome | 1 | 2015 | 220 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 385 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 486 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1075 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2537 | 0.030 |
Why?
| | United States | 2 | 2017 | 13828 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 182 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 317 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5051 | 0.030 |
Why?
| | Tumor Burden | 1 | 2014 | 286 | 0.030 |
Why?
| | Genes, Synthetic | 1 | 2012 | 15 | 0.020 |
Why?
| | Genes, Lethal | 1 | 2012 | 29 | 0.020 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 19 | 0.020 |
Why?
| | Doxorubicin | 1 | 2014 | 328 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 66 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 450 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3140 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3080 | 0.020 |
Why?
| | Signal Transduction | 2 | 2017 | 4926 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 454 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2010 | 2871 | 0.020 |
Why?
| | Imidazoles | 1 | 2012 | 234 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1344 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 244 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5384 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7123 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 76 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2009 | 27 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1710 | 0.020 |
Why?
| | Lymphoma | 1 | 2010 | 196 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1327 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 275 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 340 | 0.020 |
Why?
| | Catalysis | 1 | 2009 | 308 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 389 | 0.020 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.020 |
Why?
| | Adenoids | 1 | 2007 | 12 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 648 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2007 | 45 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 841 | 0.020 |
Why?
| | E2F2 Transcription Factor | 1 | 2005 | 15 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1304 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 313 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2005 | 34 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2005 | 61 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 163 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2007 | 198 | 0.010 |
Why?
| | Biliary Atresia | 1 | 2007 | 161 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 470 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1487 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1036 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1049 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 9746 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 619 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2120 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1691 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2835 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3968 | 0.010 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|